Four people have died from flesh-eating bacteria in Florida. Who is at risk?
The culprit, the bacteria Vibrio vulnificus, thrives in warm seawater. The deadly cases were seen in counties spread around Florida's extensive coastline, from Bay County in the Panhandle and Hillsborough County, where Tampa is located, on the Gulf Coast, to Broward County in southeastern Florida and St. Johns County just south of Jacksonville.
Florida has seen 11 Vibrio vulnificus cases so far this year, the state's health department says. The bacteria can get into the body through open wounds in the skin and cause the surrounding tissue to die, a condition known as necrotizing fasciitis, or flesh-eating disease, according to the Centers for Disease Control and Prevention. People can also get Vibrio vulnificus from eating contaminated foods, particularly raw oysters. It's unclear how the people in Florida were infected.
About 1 in 5 people with a Vibrio vulnificus infection die, the CDC says.
Antarpreet Jutla, an engineering professor at the University of Florida who researches Vibrio bacteria, said Vibrio vulnificus infections are still rare, though they tend to increase after hurricanes. Last year, Florida saw a total of 82 cases, which may have been exacerbated by the 'extremely active' hurricane season.
What is Vibrio vulnificus?
Vibrio vulnificus is one of over 200 species of Vibrio bacteria, said Rita Colwell, a professor emerita of microbiology at the University of Maryland.
The majority of Vibrio infections aren't harmful to humans, Jutla said. Some only affect other animals.
But Vibrio bacteria do cause about 80,000 infections in people each year, according to the Cleveland Clinic. Most of those cases are gastrointestinal. Only a small handful — 100 to 200 cases — are due to Vibrio vulnificus. Other Vibrio species, including Vibrio parahaemolyticus and Vibrio alginolyticus, are often the cause of those stomach illnesses. Another type of Vibrio, Vibrio cholorae, causes the diarrheal disease cholera.
Because Vibrio bacteria prefer warm water, they are typically found along the southeastern shores of the U.S., but are also found on the West Coast as well. As ocean temperatures warm, more cases have been found further north in recent years, Jutla said, including some in New York, Connecticut and Maryland.
Who is at risk?
Vibrio bacteria can creep in open wounds after spending time in salty or brackish water, said Dr. Norman Beatty, an infectious disease doctor at University of Florida Health. Most cases he's seen have been associated with spending extended time in the water, but he says that a brief exposure could be the 'only thing needed.'
Visible signs of an infection can start in just a few hours, Beatty said, and include redness, swelling and 'bull's-eye' blisters. The site will also be painful. If infection progresses, it can get into the bloodstream and cause sepsis, which can be deadly. Symptoms of sepsis include fever, chills and dangerously low blood pressure, according to the CDC.
People with liver cirrhosis, weakened immune systems and those over 65 are most at risk for infection, Jutla said.
Vibrio vulnificus infections can be treated with antibiotics.
How to prevent Vibrio infections
Beatty said he recommends covering up any open wounds before going into the ocean. Even a waterproof Band-Aid does the job, he said.
If people think they have an infection, they should seek care immediately, Beatty said. Delaying can be the difference between developing severe complications and a more mild infection.
'A delay in presenting to health care is truly the likely reason why most people have a more serious outcome than others,' he said. 'People who present within the same day with signs and symptoms of early infection, who receive antibiotics, can do well and can avoid a lot of these serious complications.'
This article was originally published on NBCNews.com
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Primus Sounds Alarm on Chronic Venous Insufficiency as President Trump's Diagnosis Sparks National Focus
SCOTTSDALE, ARIZONA / / July 24, 2025 / Following reports of President Donald J. Trump's diagnosis with Chronic Venous Insufficiency (CVI), Primus Pharmaceuticals, Inc. strongly calls on healthcare providers to intensify efforts to diagnose and treat this silent epidemic affecting 25-30 million Americans because only less than <10% are actually treated. Leg swelling, heaviness, and varicose veins are often dismissed as cosmetic or "normal aging," while they can signal a dangerous progression toward severe complications including thromboembolism (blood clots), debilitating pain, non-healing leg ulcers, and compromised mobility. Widespread, Under-Recognized Health Threat CVI, also known as chronic venous disease or venous reflux disease, impacts twice (2x) as many Americans as coronary heart disease, three times (3x) peripheral arterial disease, and 30 times (30x) the number of Americans who have a heart attack each year. According to CDC, up to 900,000 Americans are affected by venous thromboembolism annually, and 60,000 to 100,000 people die each year. Millions suffer daily challenges - standing, sitting, flying - due to blood pooling in the legs, worsened by inactivity or pressure. Traditional treatments - leg elevation, compression stockings or surgical procedures - are often cumbersome, uncomfortable, underutilized, and may be expensive with added health risks. Life-Changing Solution: Vasculera® Primus offers Vasculera, the only U.S. prescription product for CVI. It is specifically formulated as a medical food for the clinical dietary management of CVI. Taken once daily, this 600mg tablet delivers highly purified, bioavailable diosmin, a flavonoid sourced from oranges, in combination with a pH buffering agent and: Calms inflammation and oxidative stress Strengthens weakened vein walls Improves overall venous function Counters localized CVI blood acidosis Manufactured in the U.S., Vasculera presents a novel naturally-derived alternative to the status quo. Expert Physician Perspectives "CVI and its manifestation in skin known as stasis dermatitis is a very common condition that can lead to significant impairment and morbidity," said Dr. Mark Nestor, MD, PhD, Board-certified Dermatologist and Voluntary Professor, Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine. "Diosmin in its bioavailable form in the pharmaceutical-grade medical food Vasculera is a natural flavonoid that has scientifically proven benefit for this condition." Board-certified Vascular Surgeon Dr. Ron Bush, MD, FACS, one of the world's foremost experts in the histology and treatment of venous disease states, "CVI is a common condition, with symptoms that may vary but are consistently linked to elevated venous pressure. In my clinical experience, Vasculera has proven to be an effective treatment option. Its active ingredient, diosmin, is well-studied and widely documented for its ability to address the inflammation associated with chronic venous hypertension. Vasculera is also well-tolerated and has no significant contraindications." Robust Clinical Backing Over 60 published peer-reviewed clinical studies confirm diosmin's effectiveness in reducing leg pain, swelling, and skin deterioration associated with CVI. Vascular medicine experts recommend Vasculera's ultra-micronized diosmin as the only U.S. product for venous ulcers and CVI symptoms, both as standalone and adjunctive therapy in national treatment guidelines. Public Health Call to Action With an aging population and more time on electronic devices fueling CVI's prevalence, Primus urges clinicians to: Proactively screen all at-risk patients for CVI Integrate proven prescription metabolic therapies like Vasculera with CVI standards of care For prescribing information, visit About Primus Pharmaceuticals Primus innovates in prescription nutritional therapies targeting metabolic causes of chronic diseases across rheumatology, dermatology, and women's health. We develop and commercialize first-in-class products and novel deliveries in Rx drugs, medical foods, and medical devices to fill key unmet needs with universal patient access not provided by traditional pharma. Visit Contact Information Randy Keating Public Relations Managerrkeating@ SOURCE: Primus Pharmaceuticals View the original press release on ACCESS Newswire Sign in to access your portfolio
CBS News
14 hours ago
- CBS News
Third human case of West Nile virus in Illinois reported in DuPage County
A Third human case of West Nile virus in Illinois has been reported, this time in DuPage County. The DuPage County Health Department confirmed the case on Thursday. The department said the individual is a Glen Ellyn resident in their 50s, and the onset of symptoms was mid-July. The Centers for Disease Control and Prevention first confirmed in June that a person downstate, specifically in Southern Illinois, was hospitalized due to complications of the virus. The second was confirmed in Lake County on July 16. The resident was said to be in their 70s and became ill earlier in the month. Symptoms of West Nile virus While most people infected with the virus do not feel sick, about one in five will develop a fever and flu-like symptoms. Other symptoms include body aches, vomiting, diarrhea, or rash. Severe illness can occur in about one in 150 people and is most likely to occur in people over age 55 or with weakened immune systems. How to prevent it West Nile virus is spread to people from infected mosquitoes, most commonly in the summer. Eight out of 10 people infected do not develop symptoms, according to the CDC. Residents are also reminded to practice the three "R's"– reduce the number of mosquitoes and remove containers outside that hold water, repel mosquitoes by using insect repellent, and report areas where water sits for more than a week. There are no medications to treat the virus. The only way to combat the virus is to prevent mosquito bites.
Yahoo
16 hours ago
- Yahoo
Measles cases in US over 4.5 times higher than all of last year
Measles cases in the United States are continuing to rise after breaking a decades-long record just two weeks ago. There are now 1,319 confirmed measles cases across 39 states, according to data from the Centers for Disease Control and Prevention (CDC) updated Wednesday. This is the highest nationwide measles figure seen since 1992. National cases are more than 4.5 times higher than the entirety of last year, which had an estimated 285 cases reported. MORE: Amid growing Texas outbreak, how contagious is measles? So far, two children and one adult have died from the virus this year, the first deaths from measles in a decade. About one to three of every 1,000 children infected with measles die from respiratory and neurologic complications, according to the CDC. An overwhelming majority of this year's cases -- 92% -- are among those who were unvaccinated or whose vaccination status is unknown, CDC data shows. Measles was declared eliminated from the U.S. in 2000 due to a highly effective vaccination program, according to the CDC Childhood vaccination rates to protect against measles have been declining in recent years, CDC data shows. The rate of kindergarteners receiving state-required vaccinations dropped from 95% in the 2019-2020 school year to less than 93% in the 2023-2024 school year, according to CDC data. A 95% threshold is the ideal level to protect for herd immunity, public health experts note. This leaves about 280,000 U.S. kindergarteners, or 7.3%, without protection from the virus. MORE: Amid growing Texas outbreak, how contagious is measles? A measles vaccine became available in 1963. Prior to that, nearly all children got measles by the time they were 15 years old. It led to an estimated 500 deaths and 48,000 hospitalizations each year before the shot was widely available, according to the CDC. Children in the U.S. are recommended to receive the two-dose measles, mumps, and rubella (MMR) vaccine with the first dose at 12 to 15 months of age and the second between 4 and 6 years old. One dose is 93% effective, and two doses are 97% effective, the CDC says. A booster shot is not typically recommended for adults who already have immunity from the virus through vaccination or prior infection.
